🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

FDC Limited FDC NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.fdcindia.com

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.

READ MORE ›
₹405.00
-7.38% 1Y

Market & Price

Market Cap
₹6,593.81 Cr
Current Price
₹405.00
High / Low (52W)
₹503.28 / ₹321.10
Beta
0.15

Valuation

Stock P/E
23.42
Industry PE
37.60
Forward P/E
17.38
PEG Ratio
-
Book Value
₹149.97
Price to Book
2.70
P/S
3.04
EV/EBITDA
17.59
Dividend Yield
2.47%

Profitability & Returns

ROCE
14.86%
ROE
11.81%
ROA
6.37%
Profit Margin
12.96%
Op Margin
15.73%
EPS (Latest Qtr)
₹6.35
EPS (TTM)
₹17.29

Balance Sheet & Liquidity

Debt/Equity
0.62
Quick Ratio
1.88
Current Ratio
3.11
Debt
₹15.46 Cr
Total Assets
₹2,918.97 Cr
Current Assets
₹1,132.52 Cr
Working Capital
₹768.45 Cr

Ownership

Promoter Holding
69.95%
Chg in Prom Hold
-
FII / Inst Holding
7.52%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹6,087.33 Cr
Total Revenue (TTM)
₹2,170.93 Cr
EBITDA
₹346.10 Cr
Free Cash Flow
₹-1.74 Cr
Operating Cash Flow
₹200.45 Cr
Shares Outstanding
₹16.28 Cr
Gross Margin
67.25%
Payout Ratio
28.92%

Growth (CAGR)

Revenue 5Y
6.89%
Profit 5Y
13.19%
Revenue (YoY)
18.90%
Earnings (YoY)
166.80%

PROS

  • Profit CAGR of 13.2% over 5 years.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FDC FDC Limited NSEPHARMA 405.00 23.42 ₹6,593.81 Cr 2.47% 14.86% 11.81% 6.89% 13.19%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --491.89 Cr648.41 Cr473.03 Cr464.71 Cr584.79 Cr
Cost of Revenue --161.34 Cr209.23 Cr144.56 Cr151.55 Cr205.61 Cr
Gross Profit --330.55 Cr439.17 Cr328.47 Cr313.15 Cr379.17 Cr
Operating Expenses --292.13 Cr313.73 Cr309.85 Cr275.66 Cr287.17 Cr
Operating Income --38.42 Cr125.44 Cr18.62 Cr37.50 Cr92.01 Cr
EBITDA --70.06 Cr175.85 Cr54.44 Cr52.29 Cr156.25 Cr
Interest Expense --1.19 Cr1.17 Cr1.15 Cr1.12 Cr1.55 Cr
Pretax Income --53.31 Cr159.78 Cr38.09 Cr36.38 Cr140.35 Cr
Tax Provision --14.64 Cr38.42 Cr9.72 Cr8.08 Cr36.95 Cr
Net Income --38.67 Cr121.35 Cr28.37 Cr28.30 Cr103.40 Cr
Diluted EPS --2.387.451.751.746.35

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -1,777.83 Cr1,935.20 Cr2,108.12 Cr2,170.93 Cr
Cost of Revenue -683.73 Cr684.25 Cr736.28 Cr710.96 Cr
Gross Profit -1,094.09 Cr1,250.95 Cr1,371.84 Cr1,459.97 Cr
Operating Expenses -881.84 Cr952.32 Cr1,100.78 Cr1,173.11 Cr
Operating Income -212.25 Cr298.62 Cr271.07 Cr286.86 Cr
EBITDA -300.31 Cr439.68 Cr415.46 Cr438.83 Cr
Interest Expense -3.57 Cr3.54 Cr4.51 Cr4.99 Cr
Pretax Income -257.80 Cr396.22 Cr357.22 Cr374.60 Cr
Tax Provision -63.98 Cr91.16 Cr90.43 Cr93.18 Cr
Net Income -194.04 Cr305.22 Cr266.79 Cr281.42 Cr
Diluted EPS -11.6718.5816.3917.29

Compounded Sales Growth

5 Years:6.89%
1 Year:18.90%

Compounded Profit Growth

5 Years:13.19%
1 Year:166.80%

Stock Price Performance

1 Year:-7.38%
6 Months:+0.19%
3 Months:+8.25%
1 Month:+11.49%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,342.94 Cr2,468.09 Cr2,713.80 Cr2,918.97 Cr
Current Assets -1,026.91 Cr1,066.49 Cr1,088.72 Cr1,132.52 Cr
Cash & Equivalents -23.89 Cr25.42 Cr51.47 Cr48.68 Cr
Inventory -328.54 Cr388.89 Cr375.03 Cr355.25 Cr
Receivables -122.65 Cr117.38 Cr108.85 Cr151.72 Cr
Total Liabilities -361.54 Cr370.92 Cr432.72 Cr433.86 Cr
Current Liabilities -311.56 Cr310.62 Cr361.64 Cr364.07 Cr
Long Term Debt -56.33 L24.66 L10.97 L0
Total Debt -28.32 Cr20.52 Cr21.17 Cr15.46 Cr
Total Equity -1,982.05 Cr2,097.17 Cr2,281.08 Cr2,485.11 Cr
Shares Outstanding -16.59 Cr16.28 Cr16.28 Cr16.28 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -154.91 Cr220.77 Cr317.57 Cr200.45 Cr
Investing Cash Flow -11.13 Cr-17.08 Cr-199.51 Cr-109.93 Cr
Financing Cash Flow --179.95 Cr-202.16 Cr-92.12 Cr-93.33 Cr
Capital Expenditure --113.09 Cr-93.39 Cr-96.72 Cr-186.56 Cr
Free Cash Flow -41.82 Cr127.37 Cr220.85 Cr13.89 Cr
Net Change in Cash --13.90 Cr1.53 Cr25.94 Cr-2.80 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -61.5%64.6%65.1%67.3%
Operating Margin % -11.9%15.4%12.9%13.2%
Net Margin % -10.9%15.8%12.7%13.0%
ROE % -9.8%14.6%11.7%11.3%
ROCE % -10.4%13.8%11.5%11.2%

Shareholding Pattern

Insiders
69.95%
Institutions
7.52%
Public Float
25.05%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FDC

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space